Capricor Therapeutics Stock Jumps On Engineered Exosomes Development Pact

by Vandana Singh, Benzinga Editor

April 29, 2021 11:51 AM | 1 min read

Capricor Therapeutics CAPR has signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part of the Company's exosome technology portfolio.
Under the terms of the agreement, Capricor has exclusive rights to develop, manufacture, and commercialize, with the right to sublicense, IP related to exosome technology for applications across both vaccine and therapeutic areas.
Capricor is the co-owner of the intellectual property associated with the patent applications covered by the agreement.
Price Action: CAPR shares are up 6.6% at $4.21 during the market trading session on the last check Thursday.

Posted In: Biotech News Penny Stocks Health Care Contracts General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.